Given that the PRA level is much higher in patients with MHT than in those with mild-to-moderate hypertension, compensatory activation of renin induced by ARB or ACEI monotherapy can make it difficult to suppress the angiotensin II type 1 receptor (AT1R) adequately in MHT. Here, AGTR1 is linked to malignant hypertension.